ALT Featured in JAMA Editorial, Podcast & Research Summary. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. Banerjee R, Komarow L, Li Y, et al. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G - Antibacterial Resistance Leadership Group. Study Milestone - Enrollment Closed. OPTIMIZE G N I: Optimization of Beta-lactam Dosing in Critically Ill Patients with Suspected or Documented Antimicrobial-Resistant Gram-Negative Infections with Cystatin C.

ALT A R L G Grand Rounds Recording: Innovations in Diagnostic Trials. Michael Satlin, MD, Weill Cornell Medicine; Sarah Doernberg, MD, MAS, UC San Francisco; Ritu Banerjee, MD, PhD, Vanderbilt University. Moderator: Robin Patel, MD, D(ABMM), FIDSA, FACP, F(AAM), FAAAS, Mayo Clinic. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G Member Spotlight: Associate Director, Laboratory Center, Sarah Doernberg, MD, MAS, Professor of Clinical Medicine, University of California, San Francisco. "Caring for patients with compromised immune systems, I witness the impact of antimicrobial-resistant infections frequently. High quality, informative clinical research that advances and informs the diagnosis and treatment of these infections is critical."

ALT A R L G DOOR Endpoint for Acute Bacterial Skin and Skin Structure Infections Featured in Open Forum Infectious Diseases. Editorial, "What's Behind DOOR Number 2? Recent Applications From Post-Hoc Analyses of Infectious Diseases Randomized Clinical Trials." A R L G - Antibacterial Resistance Leadership Group

ALT Manuscript Published in Open Forum Infectious Diseases, "Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections," Howard-Anderson J, Hamasaki T, Ge L, et al. DOOR Level infographic: A scale of 1 to 5 ranging from dark green (1 = best) to bright red (5 = worst). 1 = 0 Events, 2 = 1 Event, 3 = 2 Events, 4 = Greater than or equal to 3 Events, 5 = Death. *Events include: lack of improvement with the treatment; a different problem caused by the original infection; an unwelcome event which is life-threatening or leads to a longer hospitalization or significant disability.

ALT Study Milestone: Innovations QoL Second Study. Manuscript published in JAMA Network Open, "Comparing Patient and Clinician Perceptions of Health-Related Quality of Life in Urinary Tract Infections," Howard-Anderson J, Brown M, Korn R, et al. A R L G - Antibacterial Resistance Leadership Group

ALT A R L G Clinical Trial Site Spotlight: a group photo of Dr. Natalie E. West & the Pulmonary Team at Johns Hopkins University next to a map of the northeast U.S. with a location marker pointing to Baltimore, Maryland.

ALT Congratulations! Vance Fowler, MD, MHS, Florence McAlister Distinguished Professor of Medicine, Professor of Molecular Genetics and Microbiology, Member in the Duke Clinical Research Institute. 2026 Hamao Umezawa Memorial Award, International Society of Antimicrobial Chemotherapy. A R L G - Antibacterial Resistance Leadership Group - a r l g .org

ALT ESCMID Postgraduate Course - Clinical trials in infectious diseases: from generating the initial idea to reporting final results and everything in between. A R L G - Antibacterial Resistance Leadership Group - a r l g .org

ALT Summary of Results PROOF Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants ARLG Antibacterial Resistance Leadership Group

ALT Summary of Results PROVIDE Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections ARLG Antibacterial Resistance Leadership Group

ALT Summary of Results MASTER GC Master Protocol - Gonorrhea and Chlamydia testing of extragenital specimens ARLG Antibacterial Resistance Leadership Group

ALT Summary of Results DICON Stewardship Interventions in Duke Infection Control Outreach Network community hospitals ARLG Antibacterial Resistance Leadership Group

ALT ESCMID Postgraduate Course. Clinical trials in infectious diseases: from generating the initial idea to reporting final results and everything in between. A R L G. Antibacterial Resistance Leadership Group. arlg.org

ALT Manuscript published in JAMA. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. Banerjee R, Komarow L, Li Y, et al. A R L G, Antibacterial Resistance Leadership Group.

ALT WHO Dialogue with Antibiotic Developers on Optimal Evidence Generation Across the Lifecycle. Monday, August 31, 14:00 - 16:00 CET

ALT Manuscript published in mBio. A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. Kawai A, McElheny CL, Shields RK, et al. A R L G, Antibacterial Resistance Leadership Group.

ALT Congratulations! Ahmed Babiker, MBBS, MSc; Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases; Rush University; A R L G Early Faculty Seedling Award Recipient. Top Featured Oral Abstract, Society for Healthcare Epidemiology of America (SHEA) Spring 2026 Conference. A R L G, Antibacterial Resistance Leadership Group, arlg.org

ALT Manuscript published in Antimicrobial Agents and Chemotherapy. Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study. Gottesdiener LS, Li Y, Greenwood-Quaintance KE, et al. A R L G, Antibacterial Resistance Leadership Group